Chromadex Corp. Stock Plummets to New 52-Week Low of $3.29

Chromadex Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.29 as of June 25, 2026. This significant decline highlights the company's struggles in a competitive market, particularly as it has underperformed compared to the S&P 500, which has seen a return of 20.77% over the same period. Despite a modest one-year performance of 7.47%, Chromadex has faced challenges, including a notable drop in stock value of approximately 75.58% over the past year. The company's financial metrics reveal a price-to-earnings ratio of 19.00 and a return on equity of 22.71%, indicating some level of profitability. However, the debt-equity ratio stands at -0.83, suggesting a complex financial structure. Additionally, the company has a price-to-book ratio of 4.39, reflecting its valuation in the market. With institutional holdings at 51.28%, there is a significant level of interest from larger investors, who have increased their stake by 3.96% in the last quarter. Overall, Chromadex Corp. continues to navigate a challenging landscape as it seeks to improve its market position.